T

TMS Co Ltd
TSE:4891

Watchlist Manager
TMS Co Ltd
TSE:4891
Watchlist
Price: 212 JPY -3.2% Market Closed
Market Cap: 8.5B JPY
Have any thoughts about
TMS Co Ltd?
Write Note

Operating Margin
TMS Co Ltd

0%
Current
0%
Average
-7.8%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
0%
=
Operating Profit
-1.1B
/
Revenue
0

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
JP
TMS Co Ltd
TSE:4891
8.5B JPY N/A
FR
Pharnext SCA
OTC:PNEXF
6T USD
-17 527%
US
Abbvie Inc
NYSE:ABBV
310.2B USD
28%
US
Amgen Inc
NASDAQ:AMGN
142B USD
19%
US
Gilead Sciences Inc
NASDAQ:GILD
115B USD
38%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
101.6B USD
40%
US
Epizyme Inc
F:EPE
94.1B EUR
-370%
AU
CSL Ltd
ASX:CSL
134.4B AUD
26%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.5B USD
30%
US
Seagen Inc
F:SGT
39.3B EUR
-33%
NL
argenx SE
XBRU:ARGX
36B EUR
-22%
Country JP
Market Cap 8.5B JPY
Operating Margin N/A
Country FR
Market Cap 6T USD
Operating Margin
-17 527%
Country US
Market Cap 310.2B USD
Operating Margin
28%
Country US
Market Cap 142B USD
Operating Margin
19%
Country US
Market Cap 115B USD
Operating Margin
38%
Country US
Market Cap 101.6B USD
Operating Margin
40%
Country US
Market Cap 94.1B EUR
Operating Margin
-370%
Country AU
Market Cap 134.4B AUD
Operating Margin
26%
Country US
Market Cap 78.5B USD
Operating Margin
30%
Country US
Market Cap 39.3B EUR
Operating Margin
-33%
Country NL
Market Cap 36B EUR
Operating Margin
-22%
No Stocks Found

TMS Co Ltd
Glance View

Market Cap
8.5B JPY
Industry
Biotechnology

TMS Co., Ltd. engages in the research and development of pharmaceutical products and medical devices. The company is headquartered in Fuchu-Shi, Tokyo-To and currently employs 8 full-time employees. The company went IPO on 2022-11-22. The firm conducts research and development of drug candidate substances based on the research and development results of academia and other research institutions. The current pipeline consists of drug candidates targeting soluble epoxide hydrolase (sEH), one of the enzymes in the human body. sEH inhibition has been shown to provide anti-inflammatory effects and the Company is developing sEH inhibitors for a variety of inflammatory diseases. The lead pipeline, TMS-007, has an anti-inflammatory effect by inhibiting sEH and a thrombolytic effect by acting on plasminogen, and will be clinically developed for acute cerebral infarction. TMS-008, a follow-on product in the pipeline, is being developed for various inflammatory diseases and is currently undergoing pre-clinical studies.

Intrinsic Value
103.44 JPY
Overvaluation 51%
Intrinsic Value
Price
T

See Also

Discover More
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
0%
=
Operating Profit
-1.1B
/
Revenue
0
What is the Operating Margin of TMS Co Ltd?

Based on TMS Co Ltd's most recent financial statements, the company has Operating Margin of 0%.